CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,888 enrolled
Drug / intervention
Palbociclib + an aromatase inhibitor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05361655
NCT05361655N/ACompleted
CompareCT.gov

Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as 1st Line Therapy in Metastatic Breast Cancer

Pfizer·observational·Posted May 5, 2022·Updated Jun 7, 2024

In Brief

An observational study evaluating Palbociclib + an aromatase inhibitor and Aromatase inhibitor for Metastatic Breast Cancer. Completed, enrolled 2,888 participants across 1 site.

Detailed Summary

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 5, 2022
Enrollment StartSep 1, 2021
Primary CompletionSep 1, 2021
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 4.2 years ago

Interventions

Palbociclib + an aromatase inhibitordrug

Palbociclib + an aromatase inhibitor therapy

Aromatase inhibitordrug

Aromatase inhibitor therapy